Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H4Cl3IO |
Molecular Weight | 361.391 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(Cl)=C(Cl)C=C1OCC#CI
InChI
InChIKey=CTETYYAZBPJBHE-UHFFFAOYSA-N
InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2
Haloprogin is an active synthetic antifungal and antimonilial agent that was effective in the treatment of superficial fungal and monilial infections of the skin. Because of these two basic therapeutic effects, haloprogin was especially useful in the treatment of infections when the identity of the specific causative organism had not been established or is being determined. Studies in-vitro demonstrated antifungal, antimonilial and antibacterial activity. It was shown to demonstrate marked in-vitro activity against Staphylococcus and Streptococcus. Haloprogin is no longer available in the US.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5422306
Curator's Comment: Preliminary data on the antifungal properties of haloprogin, originally identified as M1028, were reported by Seki and associates in 1964.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Haloprogin: a topical antifungal agent. | 1970 May |
|
Haloprogin: mode of action studies in Candida albicans. | 1974 Sep |
|
In vitro activity of ME1401, a new antifungal agent. | 1986 Nov |
|
Synthesis and quantitative structure-activity relationship analysis of N-triiodoallyl- and N-iodopropargylazoles. New antifungal agents. | 1987 Mar |
|
Synthesis and microbiological activity of some novel 5- or 6-methyl-2-(2,4-disubstituted phenyl) benzoxazole derivatives. | 1998 May 30 |
|
Synthesis and microbiological activity of some N-(o-hydroxyphenyl)benzamides and phenylacetamides as the possible metabolites of antimicrobial active benzoxazoles: part II. | 2000 Jun-Jul |
|
2,4-Dichloro-1-[1-(2,4-dichloro-benz-yl-oxy)eth-yl]benzene. | 2009 Dec 16 |
|
Gabapentin-lactum-chloranilic acid (1/1). | 2009 Dec 16 |
|
11-[3-(Dimethyl-amino)prop-yl]-6,11-dihydro-dibenzo[b,e]thiepin-11-ol. | 2009 Dec 16 |
|
6,11-Dihydro-dibenz[b,e]oxepin-11-one. | 2009 Dec 16 |
|
(E)-2-[(2-Hydr-oxy-5-nitro-phen-yl)iminiometh-yl]phenolate. | 2009 Feb 11 |
|
Propiverinium picrate. | 2009 Jul 1 |
|
2-Amino-5-nitro-phenyl 2-chloro-phenyl ketone. | 2009 Jul 18 |
|
A second polymorph of (2E)-1-(4-fluoro-phen-yl)-3-(3,4,5-trimethoxy-phen-yl)prop-2-en-1-one. | 2009 Jul 25 |
|
Violacein-producing Collimonas sp. from the sea surface microlayer of costal waters in Trøndelag, Norway. | 2009 Nov 12 |
|
1-(2-Methyl-5-nitro-phenyl)guanidinium picrate. | 2009 Oct 17 |
|
Environmental stresses inhibit splicing in the aquatic fungus Blastocladiella emersonii. | 2009 Oct 29 |
|
2-Bromo-N'-[(2Z)-butan-2-yl-idene]-5-methoxy-benzohydrazide. | 2009 Oct 31 |
|
(E)-3-[(3-Bromo-phen-yl)imino-meth-yl]benzene-1,2-diol: a combined X-ray and computational structural study. | 2009 Sep 9 |
|
5,7-Dimethyl-2,3-dihydro-1H-1,4-diazepin-4-ium picrate. | 2010 Apr 28 |
|
Dibenzo[b,e]thiepin-11(6H)-one. | 2010 Jan 13 |
|
Chlorimipraminium picrate. | 2010 Jan 13 |
|
N,N'-Bis-[(E)-2-fluoro-benzyl-idene]-1-(2-fluoro-phen-yl)methane-diamine. | 2010 Jan 23 |
|
Simultaneous spectrophotometric estimation of haloperidol and trihexyphenidyl in tablets. | 2010 Mar |
Sample Use Guides
1% cream or solution applied liberally to the affected area twice daily
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5422306
The in vitro fungistatic concentrations were determined by a serial dilution method using Sabouraud's liquid medium. The concentration of drug tested ranged from 0.19 to 100 ug/ml. All tubes were inoculated with approximately 10(5) viable macrospores obtained by washing the surface of a 14-day slant culture of the test dermatophyte with Sabouraud's liquid medium and diluting to the desired concentration. The inoculated assay tubes were incubated at room temperature (28 Celsius) for 7 days and examined for visible growth.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
||
|
WHO-ATC |
D01AE11
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
||
|
CFR |
21 CFR 333.210
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
||
|
WHO-VATC |
QD01AE11
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1355
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
M1184
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | Merck Index | ||
|
C65842
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
100071
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
DB00793
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
2263
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
3561
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
212-286-6
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
26422
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | RxNorm | ||
|
AIU7053OWL
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
DTXSID9046865
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
C100276
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
SUB08008MIG
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
CHEMBL1289
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
HALOPROGIN
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
777-11-7
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY | |||
|
100000083926
Created by
admin on Thu Jul 06 21:36:39 UTC 2023 , Edited by admin on Thu Jul 06 21:36:39 UTC 2023
|
PRIMARY |
ACTIVE MOIETY